The PCRS has updated the format of the Opioid Substitution Scheme (OOS) prescription format. The new prescription format now includes a section titled “opioid overdose therapy (for emergency use only)”. This change enables prescribers to prescribe Nyxoid® 1.8mg/0.1ml nasal spray (Naloxone hydrochloride dihydrate) to their patients by ticking the corresponding box.
These new prescription pads have already been distributed to methadone prescribers; however, the new section “opioid overdose therapy (for emergency use only)” is not ‘live’ yet. Therefore, if you are presented with an OSS prescription with the Nyxoid® 1.8mg/0.1ml nasal spray (Naloxone hydrochloride dihydrate) ticked, for PCRS reimbursement purposes you will need to request for the prescriber to write a GMS prescription.
Naloxone is recommended by the World Health Organisation for the treatment of an opioid overdose, (for example methadone). Due to the nature of this medicinal product, counselling on the appropriate use of Nyxoid® 1.8mg/0.1ml nasal spray to patients, their carers and/or family members is very important. To support you with this, Napp pharmaceuticals Ltd, manufacturers of Nyxoid® 1.8mg/0.1ml nasal spray, have made a support video with instructions on how to use this medicinal product.
